TY - JOUR
T1 - Adult-onset mitochondrial movement disorders
T2 - a national picture from the Italian Network
AU - Montano, V.
AU - Orsucci, D.
AU - Carelli, V.
AU - la Morgia, C.
AU - Valentino, M. L.
AU - Lamperti, C.
AU - Marchet, S.
AU - Musumeci, O.
AU - Toscano, A.
AU - Primiano, G.
AU - Santorelli, F. M.
AU - Ticci, C.
AU - Filosto, M.
AU - Rubegni, A.
AU - Mongini, T.
AU - Tonin, P.
AU - Servidei, S.
AU - Ceravolo, R.
AU - Siciliano, G.
AU - Mancuso, Michelangelo
N1 - Funding Information:
This work was partially supported by Telethon Grant GUP09004, Telethon-MITOCON grant GSP16001. C.L. and M.M. are supported by RF-2016-02361495 and by the EJPRD2019 project GENOMIT. VC and CLM are supported by the Italian Ministry of Health (ricerca corrente funding) and by the Emilia Romagna Region (ER-MITO project). We are grateful to the European Reference Network EURO-NMD (T.M., C.L., A.T., O.M., M.F., S.S., G.P., M.M. and G.S. as Representatives for the Italian HCP partners).
Funding Information:
This work was partially supported by Telethon Grant GUP09004, Telethon-MITOCON grant GSP16001. C.L. and M.M. are supported by RF-2016-02361495 and by the EJPRD2019 project GENOMIT. VC and CLM are supported by the Italian Ministry of Health (ricerca corrente funding) and by the Emilia Romagna Region (ER-MITO project). We are grateful to the European Reference Network EURO-NMD (T.M., C.L., A.T., O.M., M.F., S.S., G.P., M.M. and G.S. as Representatives for the Italian HCP partners).
Funding Information:
Open access funding provided by Università di Pisa within the CRUI-CARE Agreement.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/3/1
Y1 - 2022/3/1
N2 - INTRODUCTION: Both prevalence and clinical features of the various movement disorders in adults with primary mitochondrial diseases are unknown. METHODS: Based on the database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases", we reviewed the clinical, genetic, neuroimaging and neurophysiological data of adult patients with primary mitochondrial diseases (n = 764) where ataxia, myoclonus or other movement disorders were part of the clinical phenotype. RESULTS: Ataxia, myoclonus and movement disorders were present in 105/764 adults (13.7%), with the onset coinciding or preceding the diagnosis of the mitochondrial disease in 49/105 (46.7%). Ataxia and parkinsonism were the most represented, with an overall prevalence at last follow-up of 59.1% and 30.5%, respectively. Hyperkinetic movement disorders were reported in 15.3% at last follow-up, being the less common reported movement disorders. The pathogenic m.8344A > G and POLG variants were always associated with a movement disorder, while LHON variants and mtDNA single deletions were more commonly found in the subjects who did not present a movement disorder. The most common neuroimaging features were cortical and/or cerebellar atrophy, white matter hyperintensities, basal ganglia abnormalities and nigro-striatal degeneration. Almost 70% of patients with parkinsonism responded to dopaminergic therapy, mainly levodopa, and 50% with myoclonus were successfully treated with levetiracetam. CONCLUSION: Movement disorders, mainly ataxia and parkinsonism, are important findings in adult primary mitochondrial diseases. This study underlies the importance of looking for a mitochondrial etiology in the diagnostic flowchart of a movement disorder and may help direct genetic screening in daily practice.
AB - INTRODUCTION: Both prevalence and clinical features of the various movement disorders in adults with primary mitochondrial diseases are unknown. METHODS: Based on the database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases", we reviewed the clinical, genetic, neuroimaging and neurophysiological data of adult patients with primary mitochondrial diseases (n = 764) where ataxia, myoclonus or other movement disorders were part of the clinical phenotype. RESULTS: Ataxia, myoclonus and movement disorders were present in 105/764 adults (13.7%), with the onset coinciding or preceding the diagnosis of the mitochondrial disease in 49/105 (46.7%). Ataxia and parkinsonism were the most represented, with an overall prevalence at last follow-up of 59.1% and 30.5%, respectively. Hyperkinetic movement disorders were reported in 15.3% at last follow-up, being the less common reported movement disorders. The pathogenic m.8344A > G and POLG variants were always associated with a movement disorder, while LHON variants and mtDNA single deletions were more commonly found in the subjects who did not present a movement disorder. The most common neuroimaging features were cortical and/or cerebellar atrophy, white matter hyperintensities, basal ganglia abnormalities and nigro-striatal degeneration. Almost 70% of patients with parkinsonism responded to dopaminergic therapy, mainly levodopa, and 50% with myoclonus were successfully treated with levetiracetam. CONCLUSION: Movement disorders, mainly ataxia and parkinsonism, are important findings in adult primary mitochondrial diseases. This study underlies the importance of looking for a mitochondrial etiology in the diagnostic flowchart of a movement disorder and may help direct genetic screening in daily practice.
KW - Ataxia
KW - Mitochondrial disorders
KW - Movement disorders
KW - Parkinsonism
UR - http://www.scopus.com/inward/record.url?scp=85125000416&partnerID=8YFLogxK
U2 - 10.1007/s00415-021-10697-1
DO - 10.1007/s00415-021-10697-1
M3 - Article
C2 - 34259909
SN - 0340-5354
VL - 269
SP - 1413
EP - 1421
JO - Journal of Neurology
JF - Journal of Neurology
IS - 3
ER -